Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,706.00-2.95%ETH$2,577.23-5.06%GOLD$4,146.90-0.96%OIL$89.96+0.58%
Smart Investors Daily
SID Premium
DM

NASDAQ · DMAC

DiaMedica Therapeutics Inc.

Healthcare · Biotechnology

$8.13

Down-$0.29 (-3.44%)

Updated Oct 7, 2026, 9:32 AM

SID Score

5.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
486.92M
P/E ratio
-13.58
Dividend yield
0.00%
52-week range
$5.25 – $8.63
Volume
242.32K
Avg. volume
389.45K

Price performance · DMAC

DMAC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

DMAC closed at $8.13 after 21 trading sessions, up 24.31% for the selected period.

Last close
$8.13
Period change
+24.31%
Period low
$6.47
Period high
$8.42
Daily close
View OHLC price history
DMAC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$8.50$8.61$8.05$8.13242.32K
Oct 5, 2026$8.23$8.63$8.19$8.42231.38K
Oct 2, 2026$8.49$8.61$8.02$8.23335.68K
Oct 1, 2026$8.33$8.54$8.10$8.35234.22K
Sep 30, 2026$8.27$8.60$8.19$8.27219.11K
Sep 29, 2026$8.30$8.3808$8.0301$8.20231.06K
Sep 28, 2026$7.86$8.55$7.7889$8.32362.95K
Sep 25, 2026$7.85$8.00$7.44$7.94236.35K
Sep 24, 2026$7.57$7.89$7.43$7.83209.25K
Sep 23, 2026$7.70$7.75$7.34$7.56174.14K
Sep 22, 2026$7.34$7.80$7.30$7.78312.08K
Sep 21, 2026$6.86$7.35$6.825$7.26281.82K
Sep 18, 2026$6.85$6.94$6.755$6.85194.96K
Sep 17, 2026$6.75$7.00$6.675$6.85257.77K
Sep 16, 2026$6.55$6.74$6.46$6.63187.27K
Sep 15, 2026$6.55$6.65$6.36$6.53157.94K
Sep 14, 2026$6.49$6.65$6.44$6.55145.61K
Sep 11, 2026$6.57$6.877$6.33$6.47123.61K
Sep 10, 2026$6.57$6.665$6.30$6.47182.44K
Sep 9, 2026$6.50$6.9743$6.50$6.59167.13K
Sep 8, 2026$6.70$6.71$6.53$6.54119.06K

Latest DMAC news

The latest Smart Investors Daily articles mentioning DMAC.

Stock researchCompany · Overview

DMAC research

Overview

Company profile and research snapshot.

Company profile

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$8.33
Implied upside
—
Analysts
11
DMAC recent ratings
DateFirmRatingTarget
Aug 11, 2026HC Wainwright & Co.Buy—
Nov 14, 2025Cantor FitzgeraldOverweight—
Aug 15, 2025HC Wainwright & Co.Buy—
Jul 18, 2025Lake StreetBuy—
Jul 18, 2025Craig-HallumBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

MINNEAPOLIS, September 30, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it will host a virtual key opinion leader (KOL) event on October 23, 2026 at 8:00am Eastern Time to discuss fetal growth restriction (FGR), the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment for FGR and preli

Yahoo · Sep 2, 2026

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

MINNEAPOLIS, September 02, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By